-
COVID and Flu May Activate Breast Cancer Cells in Lungs
COVID and Flu May Activate Breast Cancer Cells in Lungs Aug 20, 2025 People with a history of breast cancer may want to consider COVID and flu vaccinations, according to the researchers. Read more…
-
Adding Tukysa to First Treatments Delays Growth of Metastatic HER2-Positive Breast Cancer
Adding Tukysa to First Treatments Delays Growth of Metastatic HER2-Positive Breast Cancer Dec 22, 2025 Delaying cancer growth may keep people out of the chemo chair. Read more…
-
Giredestrant Reduces Recurrence Risk More Than Tamoxifen, Aromatase Inhibitors
Giredestrant Reduces Recurrence Risk More Than Tamoxifen, Aromatase Inhibitors Dec 22, 2025 Results from the lidERA trial suggest that giredestrant could be a new standard of care for early-stage hormone receptor-positive breast cancer. Read more…
-
Proton Therapy Better Than Traditional Radiation for Leptomeningeal Disease
Proton Therapy Better Than Traditional Radiation for Leptomeningeal Disease Jan 6, 2026 When treating breast cancer that’s spread to the cerebrospinal fluid, proton therapy controlled the cancer better than traditional X-ray radiation. Read more…
-
Breaking Research News from Breastcancer.org
Breastcancer.org strives to bring you updates on the latest breast cancer research through its Research News program. Medical experts at Breastcancer.org provide easy-to-understand summaries of what the research means for YOU. Favorite this thread to get notifications on all the breaking news about current breast cancer…
-
Podcast: Top Research From SABCS 2025
Top Research From SABCS 2025 December 12, 2025 The 2025 San Antonio Breast Cancer Symposium featured four days filled with new research findings, poster presentations, and educational sessions. Marisa Weiss, MD, founder and chief medical officer of Breastcancer.org, offers her take on the top results. Listen to the episode…
-
SABCS 2025 Breastcancer.org Coverage
Nearly 11,000 scientists, healthcare professionals, and advocates have gathered at the 2025 San Antonio Breast Cancer Symposium to exchange ideas about the latest developments in breast cancer. Special sessions this year will focus on breast cancer in younger women, the interaction between breast cancer treatment and…
-
Adding Cannabis to Standard Medicines Offers Better Nausea Control for People With Cancer
Adding Cannabis to Standard Medicines Offers Better Nausea Control for People With Cancer Sep 9, 2024 But there’s a tradeoff: People taking cannabis reported feeling more anxious and dizzy than people who didn’t take cannabis. Read more…
-
Radiation & tamoxifen - necessary...?
Hi everyone, I’d really appreciate hearing from others in a similar situation. I’m in my early 40s, no kids, not close to menopause, and recently had a lumpectomy for a 12 mm, grade 1, ER+/PR+ HER2- IDC (plus a small area of DCIS). Margins were clear, and there was no lymph node involvement. My Ki-67 is low (10%), and I’ve…
-
Keytruda Improves Survival in Triple-Negative Breast Cancer
Keytruda Improves Survival in Triple-Negative Breast Cancer September 15, 2024 People diagnosed with early-stage triple-negative breast cancer who received the immunotherapy Keytruda (chemical name: pembrolizumab) along with chemotherapy before and after surgery had better event-free survival — how long they lived without…
-
FDA Approves Kisqali for Early-Stage Breast Cancer
FDA Approves Kisqali for Early-Stage Breast Cancer September 17, 2024 Kisqali (chemical name: ribociclib) can now be used after surgery in combination with an aromatase inhibitor to treat stage II or stage III hormone receptor-positive, HER2-negative breast cancer with a high risk of recurrence. Read more…
-
New Hormonal Therapy Vepdegestrant Promising for Some Metastatic HR+ Breast Cancers
New Hormonal Therapy Vepdegestrant Promising for Some Metastatic HR+ Breast Cancers May 30, 2025 The new medicine offered more benefits than Faslodex. Read more…
-
Testing for ESR1 Mutations, Then Switching to Camizestrant Improves Outcomes for HR+ HER2- MBC
Testing for ESR1 Mutations, Then Switching to Camizestrant Improves Outcomes for Metastatic HR+ HER2- Breast Cancer May 31, 2025 After two years of follow-up, the new treatment improved survival and quality of life. Read more…
-
Camrelizumab Seems Promising As New Triple-Negative Breast Cancer Treatment
Camrelizumab Seems Promising As New Triple-Negative Breast Cancer Treatment Apr 14, 2025 Adding the immunotherapy medicine camrelizumab to chemotherapy offered better outcomes than chemotherapy alone for TNBC. Read more…
-
Trodelvy and Keytruda as First Treatment for Metastatic TNBC: A New Standard of Care?
Trodelvy and Keytruda as First Treatment for Metastatic TNBC: A New Standard of Care? May 30, 2025 People lived longer without the cancer growing when they received Trodelvy and Keytruda compared to the current standard treatment. Read more…
-
Enhertu Plus Perjeta: New First-Line Treatment for Metastatic HER2-Positive Breast Cancer?
Enhertu Plus Perjeta: New First-Line Treatment for Metastatic HER2-Positive Breast Cancer? Jun 1, 2025 The combination offered better outcomes than the THP chemo regimen. Read more…
-
Breastcancer.org Reports on ASCO 2025
Follow our breaking news page on Breast Cancer Research Highlights From ASCO 2025 Stay tuned as we update the news in the thread below!
-
Mindfulness Practices Recommended for Anxiety, Depression in People With Cancer
Mindfulness Practices Recommended for Anxiety, Depression in People With Cancer Sept 5, 2023 Two professional cancer organizations have formally recommended mindfulness practices to ease anxiety and depression in people diagnosed with cancer. Read more…
-
Should Doctors Regularly Screen for Breast Cancer Brain Metastases?
Should Doctors Regularly Screen for Breast Cancer Brain Metastases? Mar 5, 2025 Research suggests current screening guidelines for brain mets need updating. Read more…
-
One Chemo Medicine Before Surgery for Early-Stage HER2-Positive Breast Cancer May Be Better Than Two
One Chemo Medicine Before Surgery for Early-Stage HER2-Positive Breast Cancer May Be Better Than Two Feb 5, 2025 Abraxane instead of Taxotere and carboplatin led to a better response and fewer serious side effects. Read more…